FSTL1 contribute to aggressive clinical behavior in DLBCL may by activating the DIP2A/ICAM-1-mediated adhesion mechanism - 04/02/26
Abstract |
Introduction |
Despite improved outcomes in diffuse large B-cell lymphoma (DLBCL) with rituximab-based therapy, cell adhesion-mediated drug resistance (CAM-DR) remains a key mechanism of treatment resistance. The role of follistatin-like protein 1 (FSTL1) in CAM-DR has not been fully elucidated.
Methods |
We conducted a retrospective analysis of newly diagnosed DLBCL patients treated with rituximab from 2019 to 2024, with special emphasis on FSTL1 expression and clinical features, and its underlying mechanism.
Results |
FSTL1 was detectable in 74.5 % of patients. Its expression was significantly elevated in DLBCL patients compared to controls (P < 0.05) and was further increased in the RR-DLBCL group (P = 0.045). FSTL1 patients exhibited more adverse clinical features, including higher incidence of extranodal involvement, more advanced stage, elevated LDH levels, and bulky masses (all p < 0.05). FSTL1 expression patients revealed a shorter overall survival (OS) (p = 0.024) and progression-free survival (PFS) (p = 0.034), with similar trend in high FSTL1 expression (P < 0.05). In vitro, increased exogenous of FSTL1 contributed to DLBCL cell proliferation, vitality, and decreased the antibody-dependent cellular cytotoxicity (ADCC) effect, whereas FSTL1 silencing reversed this trend (P < 0.05). Pathway enrichment analysis revealed an association between FSTL1 and CAM-DR. Mechanistic experiments revealed that FSTL1 may be derived from secretion by cancer-associated fibroblasts (CAFs), interacts with DIP2A on DLBCL cells and promotes ICAM-1 expression, thereby contributing to drug resistance in DLBCL.
Conclusion |
Our findings indicate that elevated FSTL1 levels may contribute to advanced clinical characteristics and worse outcomes in DLBCL. FSTL1 contributes to drug resistance likely through DIP2a/ICAM-1-mediated adhesion mechanism.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Elevated FSTL1 expression contributes to aggressive clinical features and poor prognosis in DLBCL, possibly via an adhesion mechanism mediated by DIP2A and ICAM-1.
Elevated FSTL1 expression contributes to aggressive clinical features and poor prognosis in DLBCL, possibly via an adhesion mechanism mediated by DIP2A and ICAM-1. Le texte complet de cet article est disponible en PDF.
Highlights |
• | Elevated FSTL1 may contribute to advanced clinical characteristics and worse survival in DLBCL patients. |
• | FSTL1 contributes to rituximab resistance likely through the DIP2a/ICAM-1-mediated adhesion mechanism. |
• | FSTL1 may represent a potential therapeutic target as well as a prognostic biomarker in DLBCL. |
Keywords : FSTL1, ICAM-1, CAM-DR, DLBCL
Plan
Vol 195
Article 119071- février 2026 Retour au numéro
Article précédent
- Cyanidin-3-glucoside confers neuroprotection in ischemic stroke by targeting NOX4-mediated oxidative stress: A network pharmacology and experimental validation study
- Xiaoting Li, Yikun Gao, Yingze Ye, Jin Wang, Xiaoxing Xiong, Jiehua Zhang, Liang Wei, Lijuan Gu
- D- and L-Lactate enhance intestinal barrier function via activation of an apical HCAR1/Gαi pathway in a human colonic epithelial cell model
- Annabelle J. Milner, Priyanka Anujan, Gary S. Frost, Aylin C. Hanyaloglu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?